Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
MPI-CDG is a form of congenital disorders of N-linked glycosylation, characterized by cyclic vomiting, profound hypoglycemia, failure to thrive, liver fibrosis, gastrointestinal complications (protein-losing enteropathy with hypoalbuminaemia, life-threatening intestinal bleeding of diffuse origin), and thrombotic events (protein C and S deficiency, low anti-thrombine III levels), whereas neurological development and cognitive capacity is usually normal. The clinical course is variable even within families. The disease is caused by loss of function of the gene MPI (15q24.1).
Features include always present findings: Liver scarring (fibrosis) (hepatic fibrosis), Low muscle tone (hypotonia), Liver scarring (cirrhosis) (cirrhosis), and Enlarged liver (hepatomegaly) and others; and common findings: Proximal tubulopathy and Edema. 24 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 6 | Hepatic failure, Liver scarring (fibrosis) (hepatic fibrosis), Liver scarring (cirrhosis) (cirrhosis) |
Muscles | 3 | Low muscle tone (hypotonia), Generalized hypotonia, Villous atrophy |
Kidneys and urinary system | 2 | Proximal tubulopathy, Renal cyst |
Blood and immune system | 1 | Abnormal bleeding tendency (abnormal bleeding) |
Growth and development | 1 | Failure to thrive |
MPI encodes mannose phosphate isomerase (423 aa). Isomerase that catalyzes the interconversion of fructose-6-P and mannose-6-P and has a critical role in the supply of D-mannose derivatives required for many eukaryotic glycosylation reactions Highest expression in Cells EBV-transformed lymphocytes (31.8 TPM) and Adrenal Gland (25.9 TPM).
MPI-congenital disorder of glycosylation is caused by mutations in the MPI gene on chromosome 15.
The MPI protein participates in Defective MPI causes MPI-CDG, Synthesis of substrates in N-glycan biosythesis, and MPI isomerises Fru6P to Man6P pathways.
MPI is classified as a druggable target (Druggable Genome and Enzyme categories) with score 1.2.
Genetic testing for MPI is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for MPI-congenital disorder of glycosylation has been reported in the published literature.
Phenotype severity distribution: 11 always present features, 2 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
103 publications have been identified in PubMed for MPI-congenital disorder of glycosylation. Research spans Basic Science / Preclinical (53%), Review / Meta-Analysis (23%), and Gene Therapy / Novel Therapeutics (7%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 55 | 53% |
Research summaries | 24 | 23% |
New treatment approaches | 7 | 7% |
Patient case studies | 6 | 6% |
Disease patterns and progression | 5 | 5% |
Testing and diagnosis research | 3 | 3% |
Clinical study results | 2 | 2% |
Other research | 1 | 1% |
Garapati K (2026). [PMID: 41713138](https://pubmed.ncbi.nlm.nih.gov/41713138/). *Molecular genetics and metabolism*. [Diagnostic / Biomarker]
Zhao T (2026). [PMID: 41831943](https://pubmed.ncbi.nlm.nih.gov/41831943/). *Carbohydrate polymers*. [Epidemiology / Natural History]
Ünsal Y (2026). [PMID: 39975416](https://pubmed.ncbi.nlm.nih.gov/39975416/). *Journal of clinical research in pediatric endocrinology*. [Review / Meta-Analysis]
Liang C (2025). [PMID: 39807036](https://pubmed.ncbi.nlm.nih.gov/39807036/). *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*. [Basic Science / Preclinical]
Aryal RP (2025). [PMID: 39949072](https://pubmed.ncbi.nlm.nih.gov/39949072/). *Journal of inherited metabolic disease*. [Basic Science / Preclinical]
Odenthal J (2025). [PMID: 41282383](https://pubmed.ncbi.nlm.nih.gov/41282383/). *SAGE open medical case reports*. [Case Report / Case Series]
Prakash S (2025). [PMID: 40153534](https://pubmed.ncbi.nlm.nih.gov/40153534/). *The Journal of clinical investigation*. [Basic Science / Preclinical]
Zhang Y (2025). [PMID: 40962549](https://pubmed.ncbi.nlm.nih.gov/40962549/). *Zhonghua er ke za zhi = Chinese journal of pediatrics*. [Review / Meta-Analysis]
Pinho SS (2025). [PMID: 40398097](https://pubmed.ncbi.nlm.nih.gov/40398097/). *Seminars in immunology*. [Review / Meta-Analysis]
Roh T (2025). [PMID: 39904983](https://pubmed.ncbi.nlm.nih.gov/39904983/). *Nature communications*. [Epidemiology / Natural History]
Data assembled from 8 of 12 sources · Last updated Sep 20, 2026, 7:27 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about MPI-congenital disorder of glycosylation